MIRMHealthcare · BiotechnologyThe 14 Wall Street analysts covering Mirum Pharmaceuticals, Inc. hold a median 12-month price target of $153 — +90.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 24 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Mirum Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (90): The share price has been relatively steady.
Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MIRM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +90.4% from it.
Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Oct 2026 | TD Cowen | Maintains | Buy | $140 → $145 |
| 15 Oct 2026 | Stifel | Maintains | Buy | $136 → $156 |
| 13 Oct 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 13 Oct 2026 | Evercore ISI Group | Maintains | Outperform | $135 → $146 |
| 13 Oct 2026 | Morgan Stanley | Maintains | Overweight | — |
| 13 Oct 2026 | Morgan Stanley | Maintains | Overweight | $137 → $152 |
| 12 Oct 2026 | Citigroup | Maintains | Buy | $160 → $184 |
| 12 Oct 2026 | Citigroup | Maintains | Buy | — |
| 12 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $195 → $200 |
| 12 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Oct 2026 | RBC Capital | Maintains | Outperform | $135 → $155 |
| 8 Oct 2026 | RBC Capital | Maintains | Outperform | — |
| 29 Sept 2026 | Baird | Maintains | Outperform | $123 → $130 |
| 29 Sept 2026 | Baird | Maintains | Outperform | — |
| 29 Sept 2026 | Citigroup | Maintains | Buy | $145 → $160 |
| 29 Sept 2026 | Citigroup | Maintains | Buy | — |
| 28 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $140 → $195 |
| 28 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 Aug 2026 | Citizens | Reiterates | Market Outperform | — |
| 27 Aug 2026 | Citizens | Reiterates | Market Outperform | $137 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MIRM appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 23 Oct 2026, Mirum Pharmaceuticals, Inc. returned +15.8% against +14.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 16% of US stocks
Cheaper than 99% of US stocks
Cheaper than 96% of US stocks
Higher than 82% of US stocks
Higher than 70% of US stocks
Higher than 93% of US stocks
Higher than 23% of US stocks
Higher than 4% of US stocks
Higher than 2% of US stocks
Higher than 30% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Mirum Pharmaceuticals, Inc. has a market value of $5.2B and an enterprise value of $5.5B.
Revenue in the twelve months to 30 June 2026: $618.1M. The latest quarter grew 37.9% year on year.
Net income over the same four quarters: −$860.2M, a −139.2% net margin.
Diluted earnings per share, trailing twelve months: $−14.55.
Free cash flow in the twelve months to 30 June 2026: −$263.7M.
Trailing P/E: −171.1×; forward P/E: −114.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Mirum Pharmaceuticals, Inc. employs 433 people — $1.4M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Mirum Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Mirum Pharmaceuticals announced that it will participate in upcoming investor conferences.
Why it matters — MIRM watchers may note the planned investor-conference participation as a company update.
Mirum Pharmaceuticals reported inducement grants under Nasdaq Listing Rule 5635(c)(4). The excerpt provides no further details about the grants.
Why it matters — MIRM watchers may note the company’s reported inducement grants, though the excerpt does not specify their terms or recipients.
Mirum Pharmaceuticals said Livmarli met the Phase III EXPAND study goal, improving cholestatic pruritus and reducing serum bile acids. The company plans an FDA filing in 2027.
Why it matters — The study results and planned filing are relevant to MIRM watchers tracking Livmarli's clinical and regulatory progress.
The Seeking Alpha item is a transcript discussing Phase 3 EXPAND study results for maralixibat in cholestatic pruritus, including biliary atresia.
Why it matters — The transcript concerns clinical-study results for a Mirum therapy and is relevant to monitoring the company’s development programs.
Mirum Pharmaceuticals said its Phase III EXPAND study of LIVMARLI (maralixibat) met its primary endpoint and all prespecified secondary endpoints in pediatric patients with cholestatic pruritus associated with ultra-rare cholestatic liver diseases.
Why it matters — The reported study results are relevant to MIRM watchers tracking clinical progress for LIVMARLI in these rare liver diseases.
The 14 Wall Street analysts covering Mirum Pharmaceuticals, Inc. have a median 12-month price target of $153, with estimates ranging from $118 to $200. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Mirum Pharmaceuticals, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Mirum Pharmaceuticals, Inc. 67 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 24 Oct 2026, Mirum Pharmaceuticals, Inc. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (90 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +90.4% from the last close, and Ticker Nerd's factor model ranks Mirum Pharmaceuticals, Inc. 67 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Mirum Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MIRM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $118 to $200 over the next 12 months.
Mirum Pharmaceuticals, Inc. returned +15.8% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on rare and orphan diseases, with particular strength in liver and bile-acid related disorders.
The most recent item we track (Business Wire, 21 Oct 2026): "Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences". Mirum Pharmaceuticals announced that it will participate in upcoming investor conferences.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on rare and orphan diseases, with particular strength in liver and bile-acid related disorders. The company develops and commercializes approved medicines and investigational therapies designed for patients with serious conditions that have limited treatment options. Its commercial portfolio includes treatments for Alagille syndrome, progressive familial intrahepatic cholestasis, bile-acid synthesis disorders, and cerebrotendinous xanthomatosis, supported by a pipeline of additional rare-disease programs. Mirum operates as a specialty rare-disease company, combining drug development, regulatory expertise, and patient-support capabilities to serve children, adults, and families affected by complex genetic and metabolic conditions. Headquartered in Foster City, California, Mirum Pharmaceuticals plays a focused role in the global rare-disease market by bringing targeted therapies to highly specialized clinical settings.
CEO Mr. Christopher Peetz · 433 employees · United States · https://www.mirumpharma.com
